Mounjaro and the Question Nobody Answered

01

If you read one page

1. The brand's 2023 launch spot asked, "What if all I do isn't enough?" Three years later, patients repeat the question back in their own words. Nothing in the category is answering it.
2. The category sells the injection as the hurdle. Patients count the week. One shot a week can be less diabetes than a pill every morning.
3. The brand ran a campaign about not going it alone. No message in the category is addressed to the person at home. Our method wrote one.

What this is. A demonstration of Create Care's full method, run on Mounjaro's 2026 consumer campaign. Everything came from public sources: five U.S. prescribing labels (a sixth, Zepbound's, was read in editorial review), 110 trial records across more than 30 assets in the class, about sixty literature searches, the 2023 launch spot and four 2026 television spots, and patient and family discourse from seven communities, read in sequence, unprompted.

What this isn't. Client work, a pitch to Lilly, or a critique of a team. We chose the most visible brand in its category on purpose. Lilly is not a client and not a prospect, and a company that size has its own machinery for analysis. If it helps their patients, we'd be glad.

What came out

• Eight human truths, read in public patient and family discourse, and one question worth fighting for: what would have to be true for a weekly injection to feel like a decision this person made, rather than a verdict they received?
• The clinical and competitive read on that question, including the pill wave about to reach this patient first; five audience segments; and one positioning territory, "the chosen step." It is a territory and a hypothetical statement. The final positioning is always the brand team's to write.
• Fifteen personas. Eleven rated at Moderate confidence, four held as hypotheses.
• Nine message suites, a six-page brochure plan, two social concepts, one household email built to be forwarded, and three creative bridges that show the line from insight to execution. Four personas deliberately left without a message, with the reasons why. The copy is directional: it shows what each persona needs to hear, not final, MLR-ready copy.

What we don't claim

No field research was done, so nothing here rates above Moderate: observed in public discourse and consistent across sources, not validated with real people. Every persona says so in its header. Four personas are hypotheses, flagged as such, and none of the four carries a message. Savings and coverage terms are unverified; no figure appears in any copy. Nothing here is medical advice; every message is built to make a conversation with a clinician easier to start.

This was done in days as a public sample. A client engagement is five weeks, and the difference is the part that matters: your data, your team in the room, a working session on the strategic read, a validation session on the personas, and a sign-off at every gate. This run had none of that, by design. With a client, the engines run just as fast but get pointed to a deeper place by the brand team's direction. The five weeks are the human gates around them.

How the risk is held. A human signs off at every gate, and nothing goes to market from this work without one. Every claim traces to a label section, a trial, or a spot, and carries its MLR tier. The engines check each other, and where they disagreed, we show the disagreement. Four errors in our own inputs were caught and corrected before anything downstream used them, and a fifth was caught in editorial review on October 13. No respondent was simulated. Our AI platform disclosure, which names the tools we use and how they handle data, is available on request.

Under NDA. The full persona and message portfolios are available after a conversation.

02

You've seen these ads

Mounjaro ran four consumer platforms in 2026. An Olympic figure skater asking if this is your year (January). A World Cup spot that names Ozempic and sends you to a comparison page (June). Erin, a climber narrating the daily work of type 2 diabetes into a two-way radio on a mountain trail (August). Eric Stonestreet in an elevator where everyone is already on Mounjaro (September).

Four tones. One claim structure. "3 out of 4 people reached an A1C under 7%" and "some lost up to 25 pounds" are the same two numbers the brand launched with in February 2023, and they are the same two numbers in three of the four 2026 spots.

The 2023 launch spot opened with a question: "What if all I do isn't enough?" It never answered it. Nothing since has, either.

The brand got a lot of things right. Erin names the daily work of the disease in a way no rival has. World Cup is the only spot in the set that uses a claim no competitor can make. The Olympic spot discloses plainly that its athlete doesn't have the disease and doesn't take the drug.

None of this is visible from inside a brand review. All of it is visible from the outside. That's the point of running the method on a brand we don't work for: everything that follows can be checked by anyone with the label, the spots, and a weekend.

03

Three things nobody in the category has said

Each one in the same shape: what the category says, what the human said, what it would change.

1. The question the brand asked first

What the category says. Ask your doctor. The barrier is awareness, or courage about the needle.

What the human said. People are certainly asking their doctor about Mounjaro. A striking share of the discourse is people who asked and were refused, delayed, or talked out of it. One patient on two oral medicines, A1C 8.4%, asked twice and was told both times she'd be on it for the rest of her life. She sat in the car afterward with the question the doctor never answered: what's the difference between that and metformin for the rest of my life? The fear is not the needle. It is beginning something you might not be allowed to stop, or to keep. The evidence agrees with her: the Mounjaro label says nothing about what happens when you stop, and the one tirzepatide stopping trial registered in type 2 diabetes, AIM-MAINTAIN, an investigator-led study in China, has not started enrolling. (The same molecule has a withdrawal study under its obesity brand, Zepbound, in people without diabetes. Her question is about her disease, and for that there is no answer yet.) The brand's own 2023 launch spot asked "What if all I do isn't enough?" and the failure frame it set is the one patients now use on themselves.

What it would change. Getting someone to ask their doctor about Mounjaro is only the first of four gates. A patient has to convince themselves to ask first, then decide with their doctor, then bring their household along, then get through their insurer. The patients here got past the first and stalled at the doctor, on a question nobody answered: then what? How long am I on this, and what happens if I stop or lose coverage? A brand that answers "then what" plainly, before the first dose, including the honest part that nothing in the label or the type 2 diabetes trials tells you what happens when you stop, would be the only one in the category speaking to the gate that actually stops people.

2. The week, not the needle

What the category says. The injection is the hurdle. A pill is the easier story. Lilly's own next product in this disease is a pill.

What the human said. Patients weigh a treatment by how much of their week it takes, not by the device. The complaint about the daily tablet is never the tablet; it's the empty stomach, the thirty-minute wait, the alarm set early, the dose that can't be taken late. One woman, offered a pill because the injection was in short supply, wrote that she felt fobbed off, and when the pill was ruled out she wrote one word: relieved. We treat her reaction as a hypothesis, since it comes from one thread during a shortage. The wider pattern holds across many threads: nobody described choosing the injection as brave, or as giving up. The feeling of a verdict comes from starting this kind of medicine at all, regardless of whether it's a pill or a shot.

What it would change. The brand's strongest sentence isn't about strength. It's "one shot a week can be less diabetes than a pill every morning." That cuts against the category's assumption, and against the brand's own portfolio logic, which is exactly why no one has said it. The proof point rests on the daily tablet's rules. Lilly's own pill may not carry them, which is why the window on this message is the one in section 07.

3. The household nobody wrote to

What the category says. You don't have to face this alone. The brand ran a 2025 campaign built on that idea, with a celebrity and his mother.

What the human said. The spouse who finds the chocolate wrappers, the daughter who is the only one he listens to: they are locked out three ways, by confidentiality, by "none of your business," and by a forum consensus that pushing makes it worse. The campaign about not going it alone was two patients referring each other. The person at home wasn't in it. On the one platform where a family could have answered, the spots exist only as fan re-uploads with comments turned off. And what the co-manager needs isn't to understand the disease better. It's one bounded job, and permission to stop watching.

What it would change. The single most useful asset in the whole portfolio turned out to be an email the patient forwards to the people they live with: what the medicine is, why I'm on it, what you'll notice, and what to do, which is nothing, just don't push food or push me to eat.

No category campaign has addressed that person. Our method did.

Two more facts belong here as public record. The one claim no rival can make, "the first and only GIP and GLP-1 receptor agonist" for type 2 diabetes, was the headline of the brand's 2022 approval and does not appear in the spots we reviewed. Whether a mechanism claim belongs in consumer advertising is a question for the brand's counsel; we note only that it is the one sentence no rival can say. The comparative claim that does lead, from the SURPASS-2 trial against Ozempic 1 mg, is the subject of a Lanham Act suit filed by Novo Nordisk in July 2026. A challenger brand reading this has a smaller budget and the same choice: which claim carries the weight, and which one carries the risk.

04

The creative springboard

Everything below is a demonstration: who is really there, what each of them needs to hear, and the evidence-based direction the creative should take. The creative bridges are seeds for a creative team, not concepts: a scene, a line and what the visual has to prove. Concepting is its own engagement, with the brand's final positioning, its claims, and a creative director in the room.

The territory. The analysis landed on a positioning territory we're calling the chosen step: for adults with type 2 diabetes who are above goal on oral medicine and being pressured, by themselves or others, to take more action, a once-weekly injection at a dose set by what you need, so the next step is a decision you made, not a verdict you received. Two reasons to believe, both on the label. One claim recommendation the brand isn't using.

The people. Five audience segments fractured into fifteen personas: eleven patients and four co-managers. One of the fifteen exists only to keep the other fourteen from doing harm: the patient with a history of disordered eating, for whom the category's favorite benefit is also the hazard. She gets one acknowledging line in the brochure, no ad, and a rule that no messaging suite anywhere celebrates appetite.

One persona and its message suite in full, as they stand in the portfolio, because this one came out of the place where two engines disagreed:

The messages. The brochure is built as a door rather than a destination, and its honest sentence is said the same way every time it comes up: no trial has yet reported what happens to blood sugar or weight when a person with type 2 diabetes stops this medicine. It is a fair question to ask your doctor out loud.

Three creative bridges

Each sits beside the 2026 spot it would change.

The proof each bridge would be working, in the persona's own words: "I never thought of it as how much of my week it takes." "I finally have something to say." "I didn't know I was allowed to stop."

05

Why the research didn't catch it

Research participants say things that don't hold. This isn't a flaw in any one study. It's how people behave in research, and it has been documented for ninety years. In 1934, Richard LaPiere drove across the United States with a Chinese couple and was served at nearly every hotel and restaurant they entered. He then wrote to the same establishments asking whether they would accept Chinese guests. More than ninety percent said no. Sheeran and Webb's 2016 review of the intention-behavior gap found that stated intentions predict what people do only about half the time.

Traditional healthcare communications runs on exactly these inputs. A room of patients is asked what they think, fear, and want. They answer honestly, but the research setting shapes and limits the answers. The questions are about intentions. The answers are snapshots of thought from a paid participant doing their best. The real decision happens somewhere else: in the car after the visit, at the pharmacy counter, at the table when someone glances at a plate. Unprompted discourse is still what people say. The difference is that no one asked them, no one paid them, and they said it over months, not in an hour.

We call the result a Human Truth Error: a message built on what people said rather than what they do. It produces a particular kind of campaign, the Slight Strategic Miss. The brand is right about the person and wrong about the question. Everyone in the room can feel it, nobody can name it, and the usual response is to change the creative tone and refresh the messaging.

The Create Care method is built to catch the error at the input: it observes people where they speak unprompted, over time, and it puts a human at every gate, because the method's own first findings are sometimes the ones that don't hold.

06

How we know, and where we'd check with real people

Four engines ran in sequence, each in its own chat, each blind to the one before it except through the human. The Design Thinker found the human truth from unprompted discourse. The AI Insight Lab™ found the strategic truth from the labels, the trials, the filings, and the court record, and checked the Design Thinker's sources against the primary documents. The Persona Architect fractured the audience. The Messaging Architect™ wrote to each person, inside the label. A human read every output, approved it or pushed for deeper research, and wrote the positioning statement himself.

Where the engines disagreed, and what the disagreement produced. The Lab proposed that the arrival of pills would make the injection a choice rather than a verdict. The human sent the Design Thinker back to test it. It found no patient anywhere describing the route as courage or surrender; they describe it as how much of the week it takes. The disagreement wasn't resolved by picking a side. It produced the strongest persona in the portfolio.

What the method caught in its own work. The Lab checked every citation in the Design Thinker's synthesis against the source. One human truth rested partly on a study of six Japanese adults starting basal insulin, sponsored by two drug companies; it was downgraded. A paper described as an AMA analysis was by AMA-affiliated researchers writing in a personal capacity; the attribution was corrected. The wrong Olympian was named; fixed. A line was attributed to the wrong spot; traced. All four were corrected before the personas were built. A fifth was caught in editorial review on October 13, after the draft was written: the draft said no label in the class carries withdrawal data. The Lab had said no label in the type 2 diabetes set. The writing widened it, and the Zepbound label proves the wider claim wrong. The Lab's own second read then found a type 2 diabetes maintenance trial of tirzepatide registered before the run and missed, so "no trial registered" became "no trial has reported." A case study about Human Truth Error would be dishonest if it didn't show its own.

What no single participant predicted. Two findings changed the work, and neither came from one place. The failure frame the Design Thinker heard in patients turned out to trace to the brand's own 2023 launch spot; it took the Design Thinker to hear it, the Lab to fail to source it, and a human to go and watch the ad. And the Lab's pill-wave logic was overturned by one woman on a forum saying she felt fobbed off. The method is built for this: diagnose before you prescribe, don't accept the first answer, treat silence as data, and let every part of the system check the others.

The pushes. The Lab marked four follow-up questions as non-blocking. The human sent them back for more research before any persona was built. When the Design Thinker reported that family reaction to a campaign was unobservable, the human pushed again, and a direct read of the platform turned a silence into an observation. The Messaging Architect's own test sent one suite back to be rebuilt: its first draft reached for the needle, and the brief had already found that the needle wasn't the barrier.

What we'd validate with real people. This work is online-derived, so its ceiling is Moderate. That ceiling is useful: a fast online read tells a brand which questions are worth paying real people to answer, so the research budget goes to a few sharp questions instead of a broad study. This one names what it would check next: whether "fobbed off" holds when the pill is the planned first offer and not a shortage fallback; whether the failure frame lands differently by gender, from a single thread we refused to generalize; and what happens to the person at home twelve months in, which no one has observed because adult children stop posting the moment a parent gets better. Those are three human-centered research briefs right there. Simulated respondents are great for test environments. Real people connect better with real evidence. These questions need real people.

What the reference block carries. Every claim in every message has a reference, a label section, and an MLR tier. Weight is never a headline. No cost figure appears anywhere. Hypothesis-level lines carry their flag inline. The full reference block is in the portfolio.

07

Why now

Mounjaro's clock is running. Lilly's own daily pill, approved for obesity in April, has a type 2 diabetes application in front of FDA, and approval would route this patient to a tablet first. Ozempic's list price drops to 675 dollars on January 1, 2027, alongside a Medicare-negotiated price for semaglutide, and Novo is advertising savings for up to 48 months. FDA has cited Ozempic advertising twice in a year, most recently an untitled letter in February 2026 over efficacy and superiority claims, and a proposed rule on broadcast advertising sits on FDA's regulatory agenda for December. The comparison that leads Mounjaro's most distinctive spot sits in the middle of all of it.

None of that is a prediction. It's the public calendar. Reading it, and reading what patients were saying against it, took days, not a research cycle.

Your category has a clock too. The question isn't whether your research will eventually catch what it's missing. It's whether it will catch it inside the window you have.

08

What this looks like for your brand

If you lead a brand at a company that isn't Lilly, you have probably already used AI on it. Quietly, for the analysis, for the research, and not anywhere near legal. This is how you say so out loud: with a method behind it, a human sign-off at every gate, and a trail your MLR team can read.

A good planner with a weekend can reach some of these findings. What the weekend doesn't produce is the record: every finding tiered, every claim referenced, every correction to our own inputs on the page.

This doesn't ask you to bet a launch. The first engagement is scoped to your needs: an Evidence Pack on one pressing question, or a full run through the five-week Create Care method. Either way, you walk away with something usable, whether or not we ever work together again.

Nor does it ask you to replace your agency. As creative directors ourselves, we want to give your team, or ours, the direction, the answers, and the brief they've never had.

And it doesn't ask anyone to take our word for it. Everything above is checkable, and everything we don't claim is on the first page.

The full portfolio, the fifteen personas, the nine message suites, the brochure, the social concepts, the household email, and the complete reference block, is shared under a mutual NDA, after a conversation. That's the whole first step.

09

The receipts

The spots

Dates are iSpot publish dates, not first airings.

Corrections we made to our own inputs

Primary sources

• Mounjaro prescribing information, revised August 2026; Ozempic, Rybelsus/Ozempic tablets, Trulicity and Foundayo labels via DailyMed
• Zepbound prescribing information, section 14.1, Study 4 (randomized withdrawal), via DailyMed
• Frías et al., SURPASS-2, N Engl J Med 2021; SURPASS-CVOT, N Engl J Med 2025
• ClinicalTrials.gov, 110 records retrieved October 10, 2026, re-checked October 13; one tirzepatide maintenance trial registered in T2D (AIM-MAINTAIN, NCT07555730, not yet recruiting), none reported
• Rodriguez et al., GLP-1 discontinuation and reinitiation, JAMA Netw Open 2025
• Lilly: FDA approves Mounjaro, "the first and only GIP and GLP-1 receptor agonist" for adults with type 2 diabetes, May 2022
• Novo Nordisk v. Eli Lilly, D.N.J., filed July 21, 2026
• FDA, CDER: Warning Letter to Novo Nordisk, September 9, 2025 (Oprah special; Wegovy, Ozempic, Victoza); Untitled Letter, February 26, 2026 ("Ozempic vs. Random Guy" video)
• FDA Unified Agenda, RIN 0910-AJ14, direct-to-consumer broadcast advertising (adequate provision), proposed rule listed for December 2026
• Novo Nordisk: Ozempic list price and savings program announcements, 2026; ozempic.com savings terms
• Lilly: Foundayo (orforglipron) approval, April 2026; type 2 diabetes submission, 2026
• Patient and family discourse: Diabetes UK forum, r/Mounjaro, Mayo Clinic Connect, Mumsnet, WebMD reviews, a syndicated advice column, first-person essays in the press; read in sequence, cited in the portfolio
• LaPiere, Social Forces 1934; Sheeran and Webb, Social and Personality Psychology Compass 2016